The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
118257825 11825782 5 F 2010 20160809 20151211 20160823 EXP GB-AUROBINDO-AUR-APL-2015-11249 AUROBINDO 72.00 YR F Y 0.00000 20160823 OT GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
118257825 11825782 1 PS AMLODIPINE AMLODIPINE BESYLATE 1 Unknown U U 78021
118257825 11825782 2 SS AMLODIPINE AMLODIPINE BESYLATE 1 Unknown U U 78021
118257825 11825782 3 SS HERCEPTIN TRASTUZUMAB 1 Subcutaneous 450 MG, UNK U U B1010B08,B00442B01,B104B13 0 450 MG SOLUTION FOR INJECTION
118257825 11825782 4 SS HERCEPTIN TRASTUZUMAB 1 Subcutaneous 600 MG, UNK U U B1010B08,B00442B01,B104B13 0 600 MG SOLUTION FOR INJECTION

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
118257825 11825782 1 Product used for unknown indication
118257825 11825782 2 Product used for unknown indication
118257825 11825782 3 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
118257825 11825782 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
118257825 11825782 Arthralgia
118257825 11825782 Bladder irritation
118257825 11825782 Blood pressure increased
118257825 11825782 Dizziness
118257825 11825782 Dry skin
118257825 11825782 Dysuria
118257825 11825782 Fall
118257825 11825782 Fatigue
118257825 11825782 Feeling abnormal
118257825 11825782 Gingival pain
118257825 11825782 Head injury
118257825 11825782 Hepatic neoplasm
118257825 11825782 Joint swelling
118257825 11825782 Lacrimation increased
118257825 11825782 Local swelling
118257825 11825782 Musculoskeletal stiffness
118257825 11825782 Myalgia
118257825 11825782 Nasal congestion
118257825 11825782 Neoplasm progression
118257825 11825782 Neuralgia
118257825 11825782 Onychoclasis
118257825 11825782 Photophobia
118257825 11825782 Pruritus
118257825 11825782 Rhinorrhoea
118257825 11825782 Sinus pain
118257825 11825782 Skin abrasion
118257825 11825782 Tenderness
118257825 11825782 Trigeminal neuralgia
118257825 11825782 Urinary retention
118257825 11825782 Urine flow decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found